Projects per year
Objectives: To report the baseline characteristics of patients recruited to the ENvISaGE study.
Methods: Body composition was measured by DXA, quality of life by Impact of weight on Quality of Life Assessment Tool, gastrointestinal symptoms by Gastrointestinal Symptom Rating Scale. Blood pressure, lipid profile, liver enzymes, and glycaemia was also measured. Adverse events were recorded.
Results: 12 LSG patients were matched for age, gender, and BMI against 12 ESG patients recruited in the first 6-months (mean 41.3 years, 75% female, mean BMI 37.3kg/m2). Both cohorts had substantially higher gastrointestinal symptoms and worse weight-related quality of life than population norms. LSG patients had higher HbA1c (34.0 vs 27.3mmol/mol; p=0.025), back or joint pain (6 vs 2 patients; p=0.058), and worse weight-related sexual life (12.9 vs 9.7 score; p=0.070) than ESG patients at baseline. No serious adverse events were recorded. One ESG participant had a suspected mild allergic skin reaction to routine post-procedure antibiotics.
Conclusion: The ESG appears safe for the treatment of obesity. Patients electing the ESG have similar characteristics as patients electing to undergo the LSG; however, may have fewer comorbidities.
|Publication status||Published - Sep 2019|
|Event||24th International Federation for the Surgery of Obesity and Metabolic Disorders World Congress - Madrid, Spain|
Duration: 3 Sep 2019 → 7 Sep 2019
Conference number: 24th
Bond University Nutrition and Dietetics Research Group Research Collaborations with External Clinical Partners
Marshall, S., Isenring, E., MacKenzie-Shalders, K., Kelly, J., Campbell, K., Van der Meij, B., Cox, G., Reidlinger, D., Mayr, H., Banbury, M., Nucera, R., Jenkins, J., McCray, S., Canavan, R., Parker, B., de Groot, L., Cohen, F., Rich, G., Soni, A., McCarthy, A. L., Mackay, H., Young, A. M., Hickman, I., Wilkinson, S. A., Kiss, N. & Ali, A.
1/01/14 → …